Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of SCTV01C and SCTV01E in Unvaccinated Population
NCT05308602Phase 2Withdrawn
- Sponsor
- Sinocelltech Group Limited
- Start
- Apr 2022
- Primary completion
- Aug 2022
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
01
Overview
A Phase 2 trial of sctv01c, SCTV01E in coronavirus disease 2019 (COVID-19), sponsored by Sinocelltech Group Limited. Planned start Apr 2022; status: withdrawn.
02
Drugs
sctv01cSCTV01E
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05308602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05308602.